Insulin-like growth factor I: Implications in aging

Drugs and Aging

Volumn 16, Issue 1, 2000, Pages 29-40

  Arvat, Emanuela ^a   Broglio, Fabio ^a   Ghigo, Ezio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INSULIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; AGING; BONE METABOLISM; BRAIN FUNCTION; CARDIOVASCULAR SYSTEM; HUMAN; IMMUNE SYSTEM; MUSCLE FUNCTION; NERVOUS SYSTEM; NUTRITIONAL STATUS; PRIORITY JOURNAL; PUBERTY; REVIEW; SOMATIC CELL; TISSUE SPECIFICITY;

EID: 0033966195     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016010-00003     Document Type: Review

References (157)

1. 1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16 (1): 3-34
2. 2. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18 (6): 801-31
3. 3. Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand 1991: 372 Suppl.: 107-14
4. 4. Rosen CJ, Conover C. Growth hormone/insulin-like growth factor-I axis in aging: a summary of a National Institutes of Aging-Sponsored Symposium. J Clin Endocrinol Metab 1997: 82 (12): 3919-22
5. 5. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-11, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80(8): 2534-42
6. 6. Noll K, Wegmann BR, Havemann K, et al. Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines. J Clin Endocrinol Metab 1996: 81 (7): 2653-62
7. 7. Benbassat CA, Maki KC, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 1997; 82 (5): 1484-91
8. 8. Lee PDK, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 1993; 204: 4-29
9. 9. Suikkari AM, Koivisto V, Rutanen EM, et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988; 66: 266-72
10. 10. Holly JMP, Smith CP, Dunger DB, et al. Levels of the small insulin-like growth factor binding protein are strongly related to those of insulin in prepubertal and pubertal children but only weakly so after puberty. J Endocrinol 1989; 121: 383-7
11. 11. Conover CA, Butler PC, Wang M, et al. Lack of growth hormone effect on insulin-associated suppression of insulin-like growth factor binding protein 1 in humans. Diabetes 1990; 39: 1251-6
12. 12. Lewitt MS, Baxter RC. Regulation of growth hormone-independent insulin-like growth factor-binding protein (PB-28) in cultured human fetal liver explants. J Clin Endocrinol Metab 1989; 69: 246-52
13. 13. Yamamoto H, Sohmiya M, Oka N, et al. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta Endocrinol 1991; 124: 497-500
14. 14. Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. J Clin Endocrinol Metab 1984; 13 (1): 113-43
15. 15. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64 (1): 51-8
16. 16. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78 (3): 744-52
17. 17. Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metab Clin North Am 1987; 16 (4): 995-1011
18. 18. Toogood AA, O'Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996; 81 (2): 460-5
19. 19. Ghigo E, Arvat E, Goffi S, et al. Neural control of growth hormone secretion in aged humans. In: Muller EE, Cocchi D, Locatelli V, editors. Growth hormone and somatomedins during lifespan. Berlin: Springer Verlag, 1993: 275-87
20. 20. Janssen JA, Stolk RP, Pols HAP, et al. Serum free IGF-I, total IGF-I, IGFBP-I and IGFBP-3 levels in an elderly population: relation to age and sex steroids levels. Clin Endocrinol 1998; 48: 471-8
21. 21. Janssen JA, Jacobs ML, Derkx FHM, et al. Free and total insulin-like growth factor-I (IGF-I), IGF-binding protein-1 (IGFBP-I), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2809-15
22. 22. Frystyk J, Skjaerbaek C, Dinesen B, et al. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348 (2): 185-91
23. 23. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14 (I): 20-39
24. 24. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991; 73 (5): 1081-8
25. 25. Ghigo E, Arvat E, Gianotti L, et al. Human aging and the GHIGF-I axis. J Pediatr Endocrinol Metab 1996; 9 Suppl. 3: 271-8
26. 20. Ghigo E, Goffi S, Nicolosi M. et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 1990; 71: 1481-5
27. 27. Ghigo E, Arvat E, Muccioli G, et al. Growth hormone-releasing peptides. Eur J Endocrinol 1997; 136: 445-60
28. 28. Arvat E, Gianotti L, Grottoli S, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 1994; 79: 1440-3
29. 29. Ghigo E, Arvat E, Gianotti L, et al. Aging and GH-releasing peptides. In: Bereu B, Walker R, editors. Growth hormone secretagogues. New York: Springer-Verlag, 1996: 415-31
30. 30. Arvat E, Camanni F, Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr Suppl 1997; 423: 92-6
31. 31. Ghigo E, Arvat E, Gianotti L, et al. Short-term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol 1996; 135(4): 407-12
32. 32. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-57
33. 33. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997; 66: 278-86
34. 34. O'Connor K, Stevens TE, Blackman MR. Growth hormone and aging. In: Juul A. Jørgersen JOL, editors. Growth Hormone in adults: physiological and clinical aspects. Cambridge: Cambridge University Press, 1996: 323-66
35. 35. Lieberman SA, Mitchell AM, Marcus R, et al. The insulin-like growth factor 1 generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res 1994; 26 (5): 229-33
36. 36. Arvat E, Ceda G, Ramunni J, et al. The IGF-I response to very low rhGH doses is preserved in human aging. Clin Endocrinol 1998; 49: 757-63
37. 37. Chapman IM, Hartman ML, Pezzoli SS, et al. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. J Clin Endocrinol Metab 1997; 82(9): 2996-3004
38. 38. De Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995; 16 (1): 63-86
39. 39. Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985; 33: 800-7
40. 40. Smith RG, Van der Ploeg LHT, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18 (5): 621-45
41. 41. Ghigo E, Arvat E, Aimaretti G, et al. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Baillieres Clin Endocrinol Metab 1998; 12 (2): 341-58
42. 42. Thissen J, Keteslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80-101
43. 43. Ross RJM, Chew SL. Acquired growth hormone resistance. Eur J Endocrinol 1995; 132: 655-60
44. 44. Underwood LE, Thissen JP, Lemozy S, et al. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994; 42: 145-51
45. 45. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I, and IGF binding proteins. Annu Rev Nutr 1991; 11: 393-412
46. 46. Ninh NX, Thissen JP, Maiter D, et al. Reduced liver IGF-I gene expression in young zinc deprived rats is associated with a decrease in liver GH receptors and serum GH binding protein. J Endocrinol 1995; 144: 449-54
47. 47. Devine A, Rosen C, Mohan S, et al. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women. Am J Clin Nutr 1998; 68 (1): 200-6
48. 48. Johnson TR, Blossey BK, Denko CW, et al. Expression of insulin-like growth factor-I in cultured rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 1989; 3: 580-7
49. 49. Boni-Schnetzler M, Schmid C, Meier PJ, et al. Insulin regulates insulin-like growth factor-I mRNA in rat hepatocytes. Am J Physiol 1991; 260: E846-51
50. 50. Scott CD, Baxter RC. Production of insulin-like growth factor 1 and its binding protein in rat hepatocytes cultured from diabetic and insulin-treated diabetics rats. Endocrinology 1986; 119: 2346-52
51. 51. Daughaday WH, Phillips LS, Mueller MC. The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. Endocrinology 1976; 98: 1214-19
52. 52. Phillips LS, Goldstein S, Pao CI. Nutrition and somatomedin: XXVI. Molecular regulation of IGF-I by insulin in cultured rat hepatocytes. Diabetes 1991; 40: 1525-30
53. 53. Houston B, O'Neill IE. Insulin and growth hormone act synergistically to stimulate insulin-like growth factor-I production by cultured chicken hepatocytes. J Endocrinol 1991; 128: 389-93
54. 54. Phillips LS, Young HS. Nutrition and somatomedin: II. Serum somatomedin activity and cartilage growth activity in streptozotocin-diabetic rats. Diabetes 1976; 25: 516-27
55. 55. Maes M, Ketesleger JM, Underwood LE. Low plasma somatomedin-C in streptozotocin-induced diabetes mellitus: correlation with changes in somatogenic and lactogenic liver binding sites. Diabetes 1983; 32: 1060-9
56. 56. Brismar K, Fernqvist-Forbes E, Wahren J, et al. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-I (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 872-8
57. 57. Maiter D, Fliesen T, Underwood LE, et al. Dietary protein restriction decreases insulin-like growth factor I independent of insulin and liver growth hormone binding. Endocrinology 1989; 124(5): 2604-11
58. 58. Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology 1980; 107: 1176-81
59. 59. Giacca A, Fisher SJ, Shi ZQ, et al. Insulin-like growth factor-I and insulin have no differential effects on glucose production and utilization under conditions of hyperglycemia. Endocrinology 1994; 134: 2251-8
60. 60. Lang CH, Fan J, Frost RA, et al. Regulation of the insulin-like growth factor system by insulin in burn patients. J Clin Endocrinol Metab 1996; 81: 2474-80
61. 61. Powell DR, Suwanichkul A, Cubbage ML, et al. Insulin inhibits transcription of the human gene for insulin-like growth factor binding protein-1. J Biol Chem 1991; 266: 18868-76
62. 62. Hall K, Brismar K, Grissom F, et al. IGFBP-1: production and control mechanisms. Acta Endocrinol (Copenh) 1991; 124: 46-54
63. 63. Bar RS, Boes M, Clemmons DR, et al. Insulin differentially alters transcapillary movement of intravascular IGFBP-I, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. Endocrinology 1990; 127: 497-9
64. 64. Rutanen EM, Karkkainen T, Stenman UH, et al. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab 1993; 77(5): 1152-5
65. 65. Gregoire Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth faclor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177-81
66. 66. Bereket A, Lang CH, Fan J, et al. Insulin-like growth factor binding protein (IGFBP)-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-8
67. 67. Martin FC, Yeo AL, Sonksen PH. Growth hormone secretion in the elderly: ageing and the somatopause. Baillieres Clin Endocrinol Metab 1997; 11 (2): 223-50
68. 68. Hernandez ER. Regulation of genes for insulin-like growth factor (IGF) I and II and their receptors by steroids and gonadotropins in the ovary. J Steroid Biochem Mol Biol 1995; 53: 219-1
69. 69. Attie KM, Ramirez NR, Conte FA, et al. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids. J Clin Endocrinol Metab 1990; 71: 975-83
70. 70. Gabrielsson BG, Carmignac DF, Flavell DM, et al. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology 1995; 136: 209-17
71. 71. Kelly JJ, Rajkovic IA, O'Sullivan, et al. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in postmenopausal women. Clin Endocrinol (Oxf) 1993; 39 (5): 561-7
72. 72. Dawson-Hughes B, Stern D, Goldman J, et al. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement therapy. 1986; 63: 424-9
73. 73. Wiessberger AJ, Ho KK, Lazarus LJ. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991; 72: 374-81
74. 74. Friend KE, Hartmann ML, Pezzoli SS, et al. Both oral and transdermal estrogen replacement increase GH release in postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2250-6
75. 75. Bellantoni MF, Vittone J, Campfield AT, et al. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996; 81 (8): 2848-53
76. 76. Mannor DA, Winer LM, Shaw MA, et al. Plasma growth hormone (GH)-binding proteins: effects on binding to receptors and GH action. J Clin Endocrinol Metab 1991; 73: 30-4
77. 77. Jørgensen JO, Vahl N, Hansen TB, et al. Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects. Clin Endocrinol 1998; 48 (4): 479-86
78. 78. Martha PMJ, Rogol AD, Veldhuis JD, et al. Alteration in the pulsatile properties of circulating growth hormone concentration during puberty in boys. J Clin Endocrinol Metab 1989; 69: 563-70
79. 79. Keenan BS, Richards GE, Mercado M, et al. Androgen regulation of growth hormone binding protein. Metabolism 1996; 45 (12): 1521-6
80. 80. Hobbs CJ, Plymate SR, Rosen CJ, et al. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993; 77: 776-9
81. 81. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-7
82. 82. Corpas E, Harman SM, Blackman MR. Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 1992; 24 (II): 543-5
83. 83. Juul A, Main K, Blum WF, et al. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41 (1): 85-93
84. 84. Juul A, Holm K, Kastrup KW, et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 1997; 82 (8): 2497-502
85. 85. Collet-Solberg PE, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF-I action. Endocrinol Metab Clin North Am 1996; 25: 591-614
86. 86. Bang P. Serum proteolysis of IGFBP-3. Prog Growth Factor Res 1995; 6: 285-92
87. 87. Conover CA. Insulin-like growth factor binding protein proteolysis in bone cell models. Prog Growth Factor Res 1995; 6: 301-9
88. 88. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995; 136: 5485-92
89. 89. Sonntag WE, Lynch CD, Bennet SA, et al. Alterations in insulin-like growth factor-I gene and protein expression and type I insulin-like growth factors receptors in the brains of ageing rats. Neuroscience 1999; 88(1): 269-79
90. 90. Dore S, Kar S, Rowe W, et al. Distribution and levels of [125I]IGF-1, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 1997; 80(4): 1033-40
91. 91. Stenvers KL, Lund PK, Gallagher M. Increased expression of type 1 insulin-like growth factor receptor messenger RNA in rat hippocampal formation is associated with aging and behavioral impairment. Neuroscience 1996; 72 (2): 505-18
92. 92. De Keyser J, Wilezac N, Goossens A. Insulin-like growth factor-I receptor densities in human frontal cortex and while matter during aging, in Alzheimer's disease, and in Huntington's disease. Neurosci Lett 1994; 172 (1-2): 93-6
93. 93. Willis PE, Chadan S, Baracos V, et al. Acute exercise attenuates age-associated resistance to insulin-like growth factor I. Am J Physiol 1997; 272 (3 Pt 1): E397-404
94. 94. Renganathan M, Sonntag WE, Delhono O. L-type Ca2+channel-insulin-like growth factor-I receptor signaling impairment in aging rat skeletal muscle. Biochem Biophys Res Commun 1997; 235 (3): 784-9
95. 95. Willis PE, Chadan SG, Baracos V, et al. Restoration of insulin-like growth factor I action in skeletal muscle of old mice. Am J Physiol 1998; 275 (3 Pt 1): E525-30
96. 96. Tanaka H, Liang CT. Mitogenic activity but not phenotype expression of rat osteoprogenitor cells in response to IGF-I is impaired in aged rats. Mech Ageing Dev 1996; 92 (1): 1-10
97. 97. Pfeilschifter J, Diel I, Pilz, U, et al. Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J Bone Miner Res 1993; 8 (6): 707-17
98. 98. D'avis PY, Frazier CR, Shapiro JR, et al. Age-related changes in effects of insulin-like growth factor I on human osteoblast-like cells. Biochem J 1997 15; 324 Pt 3: 753-60
99. 99. Schachtschabel DO, Freudenstein G. Diminished stimulation of hyaluronic acid synthesis by PDGF, IGF-I or serum in the senescence phase of skin fibroblast in vitro. Zeitschrift Gerontol 1994; 27 (3): 177-81
100. 100. Boulware SD, Tamborlane WV, Rennert NJ, et al. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin: dose-response relationship in healthy young and middle aged adults. J Clin Invest 1994; 93 (3): 1131-9
101. 101. Canalis E. Skeletal growth factors and aging. J Clin Endocrinol Metab 1994; 78 (5): 1009-10
102. 102. Ravn P, Overgaard K, Spencer EM, et al. Insulin-like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol 1995; 132 (3): 313-9
103. 103. Johansson AG, Eriksen EF, Lindh E, et al. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab 1997; 82 (9): 2795-8
104. 104. Kurland ES, Chan FKW, Rosen CJ, et al. Normal Growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1988; 83 (7): 2576-9
105. 105. Sugimoto T, Nishiyama K, Kuribayashi F, et al. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997; 12 (8): 1272-9
106. 106. Boonen S, Lesaffre E, Dequeker J, et al. Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss. J Am Geriatr Soc 1996; 44(11): 1301-6
107. 107. Kassem M, Brixen K, Blum W, et al. No evidence for reduced spontaneous or growth hormone stimulated serum levels of insulin-like growth factor (IGF)-I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis. Eur J Endocrinol 1994; 131: 150-5
108. 108. Bennett AE, Wahner HW, Riggs BL, et al. Insulin-like growth factors I and II: aging and bone density in women. J Clin Endocrinol Metab 1984; 59 (4): 701-4
109. 109. Pfeilschifter J, Ziegler R. Relationship between IGF-I and skeletal aging. Eur J Endocrinol 1998; 138(6): 617-8
110. 110. Moreira-Andres MN, Papapietro K, Canizo FJ, et al. Correlations between bone mineral density, insulin-like growth factor I and auxological variables. Eur J Endocrinol 1995; 132(5): 573-9
111. 111. Janssen JA, Burger H, Stolk RP, et al. Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol 1998; 138(6): 627-32
112. 112. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50-to 80-year-old men and women. J Clin Endocrinol Metab 1996; 81: 2534-40
113. 113. Seck T, Scheppach B, Scharla S, et al. Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre-and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 1998; 83(7): 2331-7
114. 114. Nicolas V, Prewett A, Bettica P, et al. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 1994; 78 (5): 1011-6
115. 115. Boonen S, Aerssens J, Dequeker J, et al. Age-associated decline in human femoral neck cortical and trabecular content of insulin-like growth factor I: potential implications for age-related (type II) osteoporotic fracture occurrence. Calcif Tissue Int 1997; 61(3): 173-8
116. 116. Rosen CJ, Donahue LR, Hunter SJ. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994; 206: 83-102
117. 117. Boonen S, Aerssen J, Dequeker J. Age-related endocrine deficiencies and fractures of the proximal femur: I Implications of growth hormone deficiency in the elderly. J Endocrinol 1996; 149: 7-12
118. 118. Eriksen EF, Kassem M, Brixen K. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis. Horm Res 1993; 40: 95-8
119. 119. Janssen JA, Stolk RP, Pols HA, et al. Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 Levels in healthy elderly individuals: relation to self-reported quality of health and disability. Gerontology 1998; 44 (5): 277-80
120. 120. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the Insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17(1):481-517
121. 121. Welle S, Thornton C, Statt M, et al. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81 (9): 3239-43
122. 122. Welle S, Thornton C. Insulin-like factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old. J Endocrinol 1997; 115: 93-7
123. 123. Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994; 79 (5): 1361-6
124. 124. Isgaard J, Nilsson A, Vilkman K, et al. Growth hormone regulates the level of insulin-like growth factor MRNA in rat skeletal muscle. J Endocrinol 1989; 120: 107-112
125. 125. Isgaard J, Kujacic V, Jennische E, et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997; 27: 517-25
126. 126. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-73
127. 127. Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990; 86: 507-15
128. 128. Mathews LS, Enberg B, Norstedt G. Regulation of rat growth hormone receptors gene expression. J Biol Chem 1989; 17: 9905-10
129. 129. Sklar MM, Kiess W, Thomas CL, et al. Developmental expression of the tissue insulin-like growth factor II/mannose 6-phosphate receptor in the rat. J Biol Chem 1989; 264: 16733-8
130. 130. Engelmann GL, Boehm KD, Haskell JF, et al. Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol 1989; 63: 1-14
131. 131. Guse AH, Kiess W, Funk B, et al. Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1,4,5-trisphosphate formation. Endocrinology 1992; 130: 145-51
132. 132. Donath MY, Gosteli-Peter MA, Froesch ER, et al. Insulin-like growth factor-I stimulates myofibrillar genes and modulates atrial natriuretic factor MRNA in rat heart. Eur J Endocrinol 1997; 137: 309-15
133. 133. Donath MY, Jenni R, Brunner HP, et al. Cardiovascular and metabolic effects of insulin-like growth factor-I at rest and during exercise in humans. J Clin Endocrinol Metab 1996; 81 (II): 4089-94
134. 134. Donath MY, Sutsch G, Yan XW, et al. Acute cardiovascular effects of insulin-like growth factor-I in patients with chronic heart failure. J Clin Endocrinol Metab 1998; 83 (9): 3177-83
135. 135. Hanson MC, Path KA, Alexander RW, et al. Induction of cardiac insulin-like growth factor I gene expression in pressure overload hypertrophy. Am J Med Sci 1993; 306: 69-74
136. 136. Donohue TJ, Dworkin LD, Lango MN, et al. Induction of myocardial insulin-like growth factor 1 gene expression in left ventricular hypertrophy. Circulation 1994; 89: 799-809
137. 137. Toyozaki T, Hiroe M, Hasumi M, et al. Insulin-like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J 1993; 57: 1120-7
138. 138. Buerke M, Murohara T, Skurk C, et al. Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 1995; 92: 8031-5
139. 139. Walsh MF, Barazi M, Pete G, et al. Insulin-like growth factor-I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996; 137(5): 1798-803
140. 140. Ceda GP, Dall'Aglio E, Magnacavallo A, et al. The insulin-like growth factor axis and plasma lipid levels in the elderly. J Clin Endocrinol Metab 1998; 83 (2): 499-502
141. 141. Botker HE, Skjaerback C, Eriksen UH, et al. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol 1997; 79(1): 961-3
142. 142. Spallarossa P, Brunelli C, Minuto H, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996; 77 (15): 200-2
143. 143. Broglio F, Fubini A, Morello M, et al. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol 1999; 50 (4): 417-30
144. 144. Muller EE. IGFs in the nervous system. New York (NY): Springer-Verlag, 1998
145. 145. Lopez-Fernandez J, Sanchez-Franco F, Velasco B, et al. Growth hormone induces somatostatin and insulin-like growth factor I gene expression in the cerebral hemispheres of aging rats. Endocrinology 1996; 137 (10): 4384-91
146. 146. D'Ercole AJ, Ye P, Gutierrez-Ospina G. Use of transgenic mice for understanding the physiology of Insulin-like growth factors. Horm Res 1996; 45 (1): 5-7
147. 147. Delafontaine P, Lou H, Alexander RW, et al. Regulation if insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension 1991; 18: 742-7
148. 148. Hansson HA, Jennische E, Skottner A. IGF-1 expression in blood vessels varies with vascular load. Acta Physiol Scand 1987; 129: 165-9
149. 149. Hansson HA, Brandsten C, Lossing C, et al. Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol 1989; 50: 125-38
150. 150. Sato Y, Okamura K, Morimoto A, et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993; 204: 223-9
151. 151. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor-I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282-91
152. 152. Nakao-Hayashi J, Ito H, Kanayasu T, et al. Stimulators effects of insulin and insulin-like growth factor-I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992; 92: 141-9
153. 153. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-I promote rat aortic angiogenesis in vitro. Am J Pathol 1994; 145: 1023-9
154. 154. Sonntag WE, Lynch CD, Cooney PT, et al. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor I. Endocrinology 1997; 138 (8): 3515-20
155. 155. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res 1996; 45 (1-2): 46-9
156. 156. Clark R. The somatogenic hormones and Insulin-like growth factor-I: of lymphopoiesis and immune function. Endocr Rev 1997; 18 (2): 157-79
157. 157. Krishnaraj R, Zaks A, Unterman T. Relationship between plasma IGF-I levels, in vitro correlates of immunity, and human senescence. Clin Immunol Immunopathol 1998; 88 (3): 264-70